Fulcrum Therapeutics Inc (FULC)

$FULC 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.

Exchange

NASDAQ

Website

www.fulcrumtx.com

$15M

Total Revenue

73

Employees

$925M

Market Capitalization

-12.53

Price/Earning ratio

Industry Peers

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 19327 2239 2.87 15.52 43.40
Organon & Co. OGN 8644 7891 -4.46 4.95 22.06
Arvinas Inc ARVN 4342 21 8.14 -26.29 -782.93
Tilray Inc TLRY 3286 513 1.23 -9.74 -71.61
ATAI Life Sciences N.V. ATAI 2545 20 5.35 -11.65 -932.88
Cronos Group Inc CRON 2114 57 1.33 -14.64 -258.59
Usana Health Sciences Inc USNA 1837 1254 4.18 13.23 11.09
Phathom Pharmaceuticals Inc PHAT 1178 7.99 -7.35 None
Fulcrum Therapeutics Inc FULC 925 15 11.21 -12.53 -481.07
Intersect ENT Inc XENT 899 103 21.80 -13.10 -66.55
Phibro Animal Health Corp. PAHC 888 833 3.68 16.16 6.53
Edgewise Therapeutics Inc EWTX 848 2.87 -31.45 None
Pliant Therapeutics Inc PLRX 657 13 2.69 -7.66 -613.56
Cyteir Therapeutics Inc CYT 637 3.42 -22.04 None
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Ikena Oncology Inc IKNA 467 10 2.52 -8.53 -551.28
Chromadex Corp CDXC 433 62 10.92 -18.30 -37.51
Rain Therapeutics Inc RAIN 404 413 2.50 -13.27 123.20
Provention Bio Inc PRVB 400 2.68 -3.12 None
Evolus Inc EOLS 321 77 4.24 -2.15 -171.53
Verrica Pharmaceuticals Inc VRCA 316 12 6.41 -8.69 -301.45
Terns Pharmaceuticals Inc TERN 263 1.46 -7.62 None
Adicet Bio Inc ACET 230 9 1.00 -4.09 -603.06
Milestone Pharmaceuticals Inc MIST 222 15 1.25 -7.50 -215.93
Kaleido Biosciences Inc KLDO 222 1 4.94 -2.49 None
LifeMD Inc LFMD 201 64 -28.62 -1.44 -133.55
Kala Pharmaceuticals Inc KALA 187 11 2.42 -1.48 None
Osmotica Pharmaceuticals Plc OSMT 181 190 2.64 -1.95 -47.85
Citius Pharmaceuticals Inc CTXR 177 2.21 -7.70 None
scPharmaceuticals Inc SCPH 162 119 2.38 -5.36 -27.05
Aquestive Therapeutics Inc AQST 146 42 -3.02 -2.27 -152.73
Eton Pharmaceuticals Inc ETON 123 15 6.11 -10.06 -74.52
Odonate Therapeutics Inc ODT 117 1.47 -1.00 None
Eyenovia Inc EYEN 113 6 12.86 -5.77 -324.94
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Opiant Pharmaceuticals Inc OPNT 90 37 2.71 -86.08 -3.06
Natural Alternatives Internati NAII 89 169 1.26 10.07 5.68
VYNE Therapeutics Inc VYNE 72 16 1.08 3.27 -554.66
India Globalization Capital In IGC 67 0 2.39 -7.65 -981.18
Mannatech Inc MTEX 66 158 2.63 10.35 4.22
Acasti Pharma Inc ACST 42 0 1.81 -2.11 -611.47
Shineco Inc TYHT 36 14 1.85 -1.78 -159.60
Assertio Holdings Inc ASRT 33 117 0.45 -0.58 -38.05
Reviva Pharmaceuticals Holding RVPH 30 1.64 -4.74 None
Baudax Bio Inc BXRX 28 1 -11.98 0.84 None
Nabriva Therapeutics Plc NBRV 28 12 0.83 -0.47 -452.55
Bio-Path Holdings Inc BPTH 28 0 1.29 -2.68 18.96
Timber Pharmaceuticals Inc TMBR 26 0 11.39 0.88 -527.55
Trevi Therapeutics Inc TRVI 26 1.67 -0.74 None
Lexaria Bioscience Corp LEXX 25 1 3.49 -6.45 -445.15
Hoth Therapeutics Inc HOTH 22 1.85 -2.29 None
Cyanotech Corp. CYAN 17 34 0.99 13.57 3.83
Sonoma Pharmaceuticals Inc. SNOA 11 17 3.13 -2.04 -31.96

Fulcrum Therapeutics Inc. (FULC) market price of $28.07 offers the impression of an exciting value play

11d ago, source: investchronicle

For the readers interested in the stock health of Fulcrum Therapeutics Inc. (FULC). It is currently valued at $28.07. When the transactions were called off in the previous session, Stock hit the highs ...

Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

8d ago, source: Yahoo Finance

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with ...

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

8d ago, source: Associated Press

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of an ...

Cramer Weighs In On Lennar, Alibaba And More

2d ago, source: Benzinga.com

Quotient Technology Inc (NYSE: QUOT) is way too risky, said Cramer. Cramer is done with Alibaba Group Holding Ltd - ADR (NYSE: BABA). He is not touching Chinese stocks. Fulcrum Therapeutics Inc ...

Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

10d ago, source: TMCnet

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment ...

Fulcrum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

7d ago, source: wallstreet online

CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with ...

Your Portfolio